{"id":65336,"date":"2026-05-14T20:18:33","date_gmt":"2026-05-14T12:18:33","guid":{"rendered":"https:\/\/flcube.com\/?p=65336"},"modified":"2026-05-14T20:18:34","modified_gmt":"2026-05-14T12:18:34","slug":"pfizers-hympavzi-gains-european-approval-for-hemophilia-with-inhibitors-novel-tfpi-targeting-therapy-offers-weekly-subcutaneous-alternative-to-factor-replacement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65336","title":{"rendered":"Pfizer&#8217;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced it has received <strong>European Commission (EC) approval<\/strong> for an <strong>indication extension<\/strong> of its <strong>Hympavzi (marstacimab)<\/strong> as a treatment for patients <strong>aged 12 years and older weighing at least 35 kg<\/strong> with <strong>hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors<\/strong>, or <strong>hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-patient-population\">Regulatory Milestone &amp; Patient Population<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Pfizer Inc. (NYSE: PFE)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Indication extension<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Ages \u226512 years, weight \u226535 kg<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Hemophilia A with FVIII inhibitors; Hemophilia B with FIX inhibitors<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>Non-factor therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovative-mechanism-of-action\">Drug Profile &amp; Innovative Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Marstacimab<\/strong> \u2013 novel non-factor therapy for hemophilia<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> <strong>&#8220;Coagulation rebalancing via targeting TFPI&#8221;<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Tissue Factor Pathway Inhibitor (TFPI)<\/strong> \u2013 natural coagulation inhibitor<\/li>\n\n\n\n<li><strong>Specific Binding:<\/strong> Targets <strong>Kunitz 2 domain of TFPI<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Goal:<\/strong> Re-establish balance between bleeding and hemostasis<\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Fixed-dose, once-weekly subcutaneous injection<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Does not replace missing clotting factors; instead modulates natural coagulation regulation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-amp-market-context\">Strategic Significance &amp; Market Context<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-addressing-high-unmet-need-population\">Addressing High-Unmet Need Population<\/h3>\n\n\n\n<p><strong>Inhibitor-Positive Hemophilia Challenge:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> ~30% of severe hemophilia A patients develop inhibitors; ~1-3% of hemophilia B patients<\/li>\n\n\n\n<li><strong>Treatment Complexity:<\/strong> Inhibitor-positive patients have limited effective treatment options<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Bypassing agents (rFVIIa, aPCC) requiring frequent intravenous administration<\/li>\n\n\n\n<li><strong>Clinical Burden:<\/strong> Higher bleeding rates, increased morbidity, and reduced quality of life<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-differentiation-advantages\">Competitive Differentiation Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-Factor Approach:<\/strong> Eliminates risk of additional inhibitor development against replacement factors<\/li>\n\n\n\n<li><strong>Subcutaneous Administration:<\/strong> Weekly dosing offers significant convenience over daily IV therapies<\/li>\n\n\n\n<li><strong>Fixed Dosing:<\/strong> Simplified regimen without need for pharmacokinetic monitoring<\/li>\n\n\n\n<li><strong>Novel Target:<\/strong> TFPI inhibition represents innovative mechanism distinct from existing therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications-amp-market-opportunity\">Commercial Implications &amp; Market Opportunity<\/h2>\n\n\n\n<p><strong>European Hemophilia Market Dynamics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Premium Pricing Potential:<\/strong> Novel mechanisms in orphan indications typically command high value<\/li>\n\n\n\n<li><strong>Reimbursement Advantage:<\/strong> Addresses critical unmet need in inhibitor-positive population<\/li>\n\n\n\n<li><strong>Market Expansion:<\/strong> Builds on existing Hympavzi franchise in broader hemophilia population<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> European approval supports worldwide regulatory filings<\/li>\n<\/ul>\n\n\n\n<p><strong>Patient-Centric Benefits:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced Treatment Burden:<\/strong> Weekly subcutaneous vs. frequent intravenous administration<\/li>\n\n\n\n<li><strong>Improved Adherence:<\/strong> Simplified fixed-dose regimen enhances compliance<\/li>\n\n\n\n<li><strong>Quality of Life:<\/strong> Potential for better bleeding control and reduced hospital visits<\/li>\n\n\n\n<li><strong>Home Administration:<\/strong> Subcutaneous format enables self-administration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pipeline-context\">Development Pipeline Context<\/h2>\n\n\n\n<p>This indication extension represents Pfizer&#8217;s continued investment in expanding Hympavzi&#8217;s therapeutic utility across the hemophilia spectrum. The approval validates the <strong>coagulation rebalancing approach<\/strong> as a viable alternative to traditional factor replacement, particularly in the challenging inhibitor-positive population.<\/p>\n\n\n\n<p>The success of marstacimab could establish <strong>TFPI targeting<\/strong> as a new standard of care for inhibitor-positive hemophilia patients, potentially displacing current bypassing agents through superior convenience and efficacy profiles.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market adoption, and therapeutic benefits of Hympavzi. Actual results may differ due to risks including competitive dynamics, reimbursement challenges, real-world effectiveness, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[863,309,15,24],"class_list":["post-65336","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nyse-pfe","tag-pfizer","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer&#039;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication extension of its Hympavzi (marstacimab) as a treatment for patients aged 12 years and older weighing at least 35 kg with hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65336\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer&#039;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication extension of its Hympavzi (marstacimab) as a treatment for patients aged 12 years and older weighing at least 35 kg with hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65336\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T12:18:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T12:18:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer&#8217;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement\",\"datePublished\":\"2026-05-14T12:18:33+00:00\",\"dateModified\":\"2026-05-14T12:18:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403-2.webp\",\"keywords\":[\"NYSE: PFE\",\"Pfizer\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65336#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65336\",\"name\":\"Pfizer's Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403-2.webp\",\"datePublished\":\"2026-05-14T12:18:33+00:00\",\"dateModified\":\"2026-05-14T12:18:34+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication extension of its Hympavzi (marstacimab) as a treatment for patients aged 12 years and older weighing at least 35 kg with hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65336\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403-2.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403-2.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer's Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65336#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer&#8217;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication extension of its Hympavzi (marstacimab) as a treatment for patients aged 12 years and older weighing at least 35 kg with hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65336","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement","og_description":"Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication extension of its Hympavzi (marstacimab) as a treatment for patients aged 12 years and older weighing at least 35 kg with hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors.","og_url":"https:\/\/flcube.com\/?p=65336","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T12:18:33+00:00","article_modified_time":"2026-05-14T12:18:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65336#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65336"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer&#8217;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement","datePublished":"2026-05-14T12:18:33+00:00","dateModified":"2026-05-14T12:18:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65336"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65336#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp","keywords":["NYSE: PFE","Pfizer","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65336#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65336","url":"https:\/\/flcube.com\/?p=65336","name":"Pfizer's Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65336#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65336#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp","datePublished":"2026-05-14T12:18:33+00:00","dateModified":"2026-05-14T12:18:34+00:00","description":"Pfizer Inc. (NYSE: PFE) announced it has received European Commission (EC) approval for an indication extension of its Hympavzi (marstacimab) as a treatment for patients aged 12 years and older weighing at least 35 kg with hemophilia A (congenital factor VIII deficiency) with factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) with factor IX (FIX) inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65336#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65336"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65336#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp","width":1080,"height":608,"caption":"Pfizer's Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65336#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer&#8217;s Hympavzi Gains European Approval for Hemophilia with Inhibitors \u2013 Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403-2.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65336"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65336\/revisions"}],"predecessor-version":[{"id":65338,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65336\/revisions\/65338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65337"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}